Inspra(Pfizer) success in REMINDER trial for acute STEMI patients
Pfizer Inc. announced results from the REMINDER trial of Inspra (eplerenone) showing statistically significant risk reductions in the primary composite efficacy endpoint. The composite endpoint was defined as the time to first event of cardiovascular (CV) mortality, re-hospitalization or extended initial hospital stay due to diagnosis of Heart Failure (HF), sustained ventricular tachycardia or fibrillation, ejection fraction (EF) 40% after 1 month, or an elevation of BNP/ NT-proBNP after 1 month.
The REMINDER trial demonstrated a statistically significant 42.9% relative risk reduction in the primary endpoint with p < 0.0001 (95% confidence interval [CI] 0.439, 0.742) in patients with acute STEMI when eplerenone was initiated within the first 24 hours of onset of symptoms.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.